JP2025503448A5 - - Google Patents

Info

Publication number
JP2025503448A5
JP2025503448A5 JP2024536125A JP2024536125A JP2025503448A5 JP 2025503448 A5 JP2025503448 A5 JP 2025503448A5 JP 2024536125 A JP2024536125 A JP 2024536125A JP 2024536125 A JP2024536125 A JP 2024536125A JP 2025503448 A5 JP2025503448 A5 JP 2025503448A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound according
acceptable form
isotopic derivative
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503448A (ja
Filing date
Publication date
Priority claimed from PCT/CN2021/138744 external-priority patent/WO2023108536A1/en
Application filed filed Critical
Priority claimed from PCT/CN2022/139649 external-priority patent/WO2023109954A1/en
Publication of JP2025503448A publication Critical patent/JP2025503448A/ja
Publication of JP2025503448A5 publication Critical patent/JP2025503448A5/ja
Pending legal-status Critical Current

Links

JP2024536125A 2021-12-16 2022-12-16 Tyk2阻害剤および組成物ならびにその方法 Pending JP2025503448A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2021/138744 WO2023108536A1 (en) 2021-12-16 2021-12-16 Tyk2 inhibitors and compositions and methods thereof
CNPCT/CN2021/138744 2021-12-16
CNPCT/CN2022/106876 2022-07-20
PCT/CN2022/106876 WO2023109120A1 (en) 2021-12-16 2022-07-20 Tyk2 inhibitors and compositions and methods thereof
PCT/CN2022/139649 WO2023109954A1 (en) 2021-12-16 2022-12-16 Tyk2 inhibitors and compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2025503448A JP2025503448A (ja) 2025-02-04
JP2025503448A5 true JP2025503448A5 (OSRAM) 2025-12-19

Family

ID=86774877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536125A Pending JP2025503448A (ja) 2021-12-16 2022-12-16 Tyk2阻害剤および組成物ならびにその方法

Country Status (10)

Country Link
US (2) US12129250B2 (OSRAM)
EP (1) EP4448514A4 (OSRAM)
JP (1) JP2025503448A (OSRAM)
KR (1) KR20240120732A (OSRAM)
CN (1) CN118401516A (OSRAM)
AU (1) AU2022412835A1 (OSRAM)
CA (1) CA3240888A1 (OSRAM)
IL (1) IL313571A (OSRAM)
TW (1) TW202339749A (OSRAM)
WO (1) WO2023109954A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120303268A (zh) * 2022-12-16 2025-07-11 津药生物科技(天津)有限公司 新型含杂环取代的丙烯酸衍生物及其用途
CN120693328A (zh) * 2023-02-07 2025-09-23 浙江华海药业股份有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024254832A1 (en) * 2023-06-15 2024-12-19 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2026026866A1 (zh) * 2024-08-02 2026-02-05 北京普祺医药科技股份有限公司 作为tyk2抑制剂的大环化合物及其药物组合物
CN120607493B (zh) * 2025-06-04 2026-04-24 江西科技师范大学 一种含嘧啶结构的酰胺类化合物及其在制备tyk2 jh2激酶抑制剂中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
CA2657260A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
JP5705720B2 (ja) 2008-04-16 2015-04-22 ポートラ ファーマシューティカルズ, インコーポレイテッド Sykまたはjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド
HRP20240097T1 (hr) 2011-04-22 2024-03-29 Signal Pharmaceuticals, Llc Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
AR093403A1 (es) 2012-11-08 2015-06-03 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
JP2014198693A (ja) 2013-03-29 2014-10-23 大鵬薬品工業株式会社 免疫疾患の予防及び/又は治療剤
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
IL274816B2 (en) 2017-11-21 2023-12-01 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
EP3768667B1 (en) * 2018-03-22 2023-04-12 Bristol-Myers Squibb Company Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba
CA3118094A1 (en) 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US20230093099A1 (en) * 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
WO2021143498A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
HUE067219T2 (hu) * 2020-03-11 2024-10-28 Beijing Innocare Pharma Tech Co Ltd Heterociklusos vegyületek a TYK2 aktivitás gátlására
TW202204344A (zh) * 2020-04-01 2022-02-01 美商永恒生物科技公司 酪胺酸激酶2抑制劑、其製備方法及醫藥用途
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
CN113563309B (zh) * 2020-04-28 2024-12-13 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
US20220002267A1 (en) 2020-06-24 2022-01-06 Eternity Bioscience Inc. Tyrosine kinase 2 inhibitors, preparation methods and medicinal uses thereof
CN113968846A (zh) 2020-07-24 2022-01-25 上海翰森生物医药科技有限公司 一种哒嗪类衍生物的盐、晶型及其制备方法和应用
JP2024504239A (ja) * 2020-12-02 2024-01-31 シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド ヒドロキサマート化合物、その調製方法及びその用途
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
TWI804266B (zh) * 2021-04-07 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 Tyk2抑制劑及其用途
US12509360B2 (en) 2021-04-16 2025-12-30 Sri Lanka Institute Of Information Technology Method of making silver-iron titanate nanoparticles and uses thereof
CN115466257A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用

Similar Documents

Publication Publication Date Title
JP2024050527A5 (OSRAM)
JP2022510925A5 (OSRAM)
JP2022505525A5 (OSRAM)
JP2021523221A5 (OSRAM)
CN115697993A (zh) 作为axl抑制剂的嘧啶类化合物
JP2022550640A5 (OSRAM)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
JP2019510787A5 (OSRAM)
JP2021523225A5 (OSRAM)
JP2021514001A5 (OSRAM)
JP2020510091A5 (OSRAM)
EP3013815B1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
RU2003105805A (ru) Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1
RU2008141368A (ru) Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3
JP2015501833A5 (OSRAM)
JP2019531279A5 (OSRAM)
CA2418868A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2022553376A5 (OSRAM)
JP2021502387A5 (OSRAM)
JP2024529527A5 (OSRAM)
JP2022552445A5 (OSRAM)
JP2022534704A5 (OSRAM)
JP2013542267A5 (OSRAM)
JP2021046404A5 (OSRAM)